18 March 2015. KEI Europe, KEI, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies — AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck. The proposed licences would permit the manufacture, import, export and sale of generic HCV medicines in every country in the world.
10 March 2015. KEI Europe submitted a request to the Government of Romania, seeking a compulsory licence on patents concerning drugs for the treatment of the hepatitis C virus (HCV). KEI Europe asked that the government take steps to permit the importation of generic versions of certain medicines used in the treatment of HCV.
1 October 2015. KEI Europe, as a member of the Coalition for Affordable T-DM1, submitted a letter to the UK government requesting the government to take several actions to make the breast cancer drug T-DM1 (trastuzumab emtansine) more affordable. The drug made by Roche (trade name Kadcyla) was declared too expensive for the NHS to provide and was only available in England through the Cancer Drug Fund.
- Other Licensing Requests for Cancer Treatments
4 August 2014. T-DM1 patents and F. Hoffmann La Roche: Request for licence to trastuzumab emtanisine (T-DM1), for territory of the member states of the European Union. T-DM1, sold under the brand name of Kadcyla by Roche, is a treatment for HER2+ breast cancer. A copy of the letter is available here.